Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

QUARTERLY UPDATE ON STATUS OF RESUMPTION

This announcement is made by Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.24A of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the "**Announcements**") of the Company dated March 27, 2026, March 30, 2026, April 1, 2026, April 21, 2026, April 27, 2026, May 3, 2026, May 26, 2026 and June 17, 2026 in relation to, among other things, the delay in publication of 2025 Annual Results, the suspension of trading in the Shares, the Resumption Guidance, the establishment of the Independent Investigation Committee and the appointment of the Investigator. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE ON THE RESUMPTION PROGRESS

The Company has devised, and is proactively implementing its resumption plan, with a view to satisfying the Resumption Guidance as soon as practicable. Specifically:

1. Independent Investigation

On June 17, 2026, the Independent Investigation Committee appointed CLA Advisory (Hong Kong) Limited as the Investigator to undertake the Independent Investigation into the Matters. The Independent Investigation Committee has considered, and was satisfied that the Investigator is independent and possesses the credentials, qualifications, experience and resources to conduct the Independent Investigation:

(i) the Investigator is an independent third party not connected with any of the substantial Shareholders, Directors, or the Company's outgoing or incoming auditors;

(ii) the Investigator will deploy a dedicated forensic team to undertake the Independent Investigation;

(iii) the engagement team has an extensive track record of successfully undertaking independent forensic investigations for companies listed on the Stock Exchange; and

(iv) the Investigator has committed to a pragmatic timetable which aligns with the Company's timetable for fulfilment of the Resumption Guidance.

See the announcement of the Company dated June 17, 2026 for details of the factors considered by the Independent Investigation Committee.

As at the date of this announcement, the Independent Investigation is ongoing. Further announcement(s) will be made by the Company to keep the Shareholders and potential investors of the Company informed of the progress and any material developments or key findings and views regarding the Independent Investigation as and when appropriate.

2. Independent internal control review

The Resumption Guidance has requested the Company to engage an independent internal control consultant (the "**Independent IC Consultant**") to conduct an independent internal control review (the "**Independent IC Review**") and demonstrate that: (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the Company to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, cash management, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information.

As of the date of this announcement, the Company and the audit committee of the Company are in the course of identifying a proper candidate to be appointed as the Independent IC Consultant to carry out the Independent IC Review as requested by the Resumption Guidance. Further announcement(s) will be made by the Company to keep the Shareholders and potential investors of the Company informed of the progress and any material developments or key findings and views regarding the Independent IC Review as and when appropriate.

3. Financial information

Reference is made to the announcement of the Company dated June 5, 2026 in relation to, among other things, the appointment of KTC Partners CPA Limited ("**KTC**") as the new Auditor. As at the date of this announcement, KTC is currently carrying out audit planning for the 2025 Annual Audit. Based on the information currently available and subject to the progress of the Independent Investigation, the 2025 Annual Audit and the 2025 Annual Results are expected to be completed by the end of September 2026. Further announcement(s) will be made by the Company to keep the Shareholders and potential investors of the Company informed of the progress regarding the 2025 Annual Audit as and when appropriate.

BUSINESS OPERATIONS

The Group is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. As at the date of this announcement, the business of the Group (including the Group's research and development affairs related to core products) has been operating as usual in all material respects. To the best knowledge of the Directors and based on preliminary assessment, the operations of the Group have not been adversely affected by the Matters and the suspension of trading in the Shares on the Stock Exchange (the "**Trading Suspension**"). The Company will continuously assess the impact of the Matters and the Trading Suspension on the Group's operations and will make further announcement(s) as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, June 29, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.